These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36106376)

  • 1. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
    Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N
    Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
    Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
    JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world assessment of comprehensive genome profiling impact on clinical outcomes: A single-institution study in Japan.
    Kunimasa K; Sugimoto N; Yamasaki T; Kukita Y; Fujisawa F; Inoue T; Yamaguchi Y; Kitasaka M; Sakai D; Honma K; Wakamatsu T; Yamamoto S; Hayashi T; Mabuchi S; Okuno J; Kawamura T; Kai Y; Urabe M; Nishimura K
    Cancer Med; 2024 Sep; 13(18):e70249. PubMed ID: 39315676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of barriers to implementation of precision oncology in patients with rare cancers.
    Takamizawa S; Koyama T; Sunami K; Sudo K; Hirata M; Kubo T; Tao K; Cho H; Narita Y; Kato K; Yamazaki N; Ohe Y; Okusaka T; Matsui Y; Ogawa C; Yonemori K; Yamamoto N
    Cancer Sci; 2024 Jun; 115(6):2023-2035. PubMed ID: 38538548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.
    Kondo T; Matsubara J; Quy PN; Fukuyama K; Nomura M; Funakoshi T; Doi K; Sakamori Y; Yoshioka M; Yokoyama A; Tamaoki M; Kou T; Hirohashi K; Yamada A; Yamamoto Y; Minamiguchi S; Nishigaki M; Yamada T; Kanai M; Matsumoto S; Muto M
    Cancer Sci; 2021 Jan; 112(1):296-304. PubMed ID: 33007138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
    Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
    J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice.
    Fukada I; Mori S; Hayashi N; Hosonaga M; Xiaofei W; Yamazaki M; Ueki A; Kiyotani K; Tonooka A; Takeuchi K; Ueno T; Takahashi S
    Cancer Sci; 2023 Dec; 114(12):4632-4642. PubMed ID: 37858313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
    Hagio K; Kikuchi J; Takada K; Tanabe H; Sugiyama M; Ohhara Y; Amano T; Yuki S; Komatsu Y; Osawa T; Hatanaka KC; Hatanaka Y; Mitamura T; Yabe I; Matsuno Y; Manabe A; Sakurai A; Ishiguro A; Takahashi M; Yokouchi H; Naruse H; Mizukami Y; Dosaka-Akita H; Kinoshita I
    Cancer Sci; 2023 Aug; 114(8):3385-3395. PubMed ID: 37208840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
    Kikuchi J; Ohhara Y; Takada K; Tanabe H; Hatanaka K; Amano T; C Hatanaka K; Hatanaka Y; Mitamura T; Kato M; Shibata Y; Yabe I; Endoh A; Komatsu Y; Matsuno Y; Sugiyama M; Manabe A; Sakurai A; Takahashi M; Naruse H; Torimoto Y; Dosaka-Akita H; Kinoshita I
    Jpn J Clin Oncol; 2021 Apr; 51(5):753-761. PubMed ID: 33532831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.
    Hilal T; Nakazawa M; Hodskins J; Villano JL; Mathew A; Goel G; Wagner L; Arnold SM; DeSimone P; Anthony LB; Hosein PJ
    BMC Cancer; 2017 Aug; 17(1):602. PubMed ID: 28854908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.
    Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
    JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
    Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
    Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of psychological distress and associated factors among patients undergoing comprehensive genomic profiling testing: protocol for a multicentre, prospective, observational study.
    Matsuoka A; Fujimori M; Koyama T; Sato A; Mori K; Hirata M; Tanabe N; Nakachi K; Kato S; Okamoto H; Ogawa K; Komatsu H; Iwasaku M; Miyaji T; Uchitomi Y
    BMJ Open; 2023 Nov; 13(11):e072472. PubMed ID: 37996226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology.
    Kubo T; Sunami K; Koyama T; Kitami M; Fujiwara Y; Kondo S; Yonemori K; Noguchi E; Morizane C; Goto Y; Maejima A; Iwasa S; Hamaguchi T; Kawai A; Namikawa K; Arakawa A; Sugiyama M; Ohno M; Yoshida T; Hiraoka N; Yoshida A; Yoshida M; Nishino T; Furukawa E; Narushima D; Nagai M; Kato M; Ichikawa H; Fujiwara Y; Kohno T; Yamamoto N
    ESMO Open; 2024 Apr; 9(4):102981. PubMed ID: 38613908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer.
    Tjota MY; Segal JP; Wang P
    J Appl Lab Med; 2024 Jan; 9(1):76-91. PubMed ID: 38167763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability of genome-matched therapy based on clinical practice.
    Hayashi N; Mori S; Ohmoto A; Fukada I; Yamazaki M; Hosonaga M; Wang X; Ueki A; Kiyotani K; Tonooka A; Takeuchi K; Takahashi S
    Int J Clin Oncol; 2024 Jul; 29(7):964-971. PubMed ID: 38668785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.
    Weinberg BA; Gowen K; Lee TK; Ou SI; Bristow R; Krill L; Almira-Suarez MI; Ali SM; Miller VA; Liu SV; Klempner SJ
    Oncologist; 2017 Feb; 22(2):152-157. PubMed ID: 28193735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
    Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
    J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.